OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
Meeting to occur in mid-September 2026 Interim 3-year Overall Survival data expected early September, 2026 Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation and Rolling Review expected following this meeting Sustained overall survival benefit observed between 2-year and 2.5-year timepoints U.K. MHRA Statistical Methods Scientific Advice Meeting gra
2026-08-13 8:45 AM EDT | OS Therapies
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as Principal Investigator of Hemostemix' VesCell™ (ACP-01) longevity clinical trial. The study is designed to investigate whether Hemostemix' VesCell™ can improve measurable dimensions of longevity including cardiovascular h
Biotechnology, Pharmaceuticals, Health
2026-08-12 8:23 AM EDT | Hemostemix Inc.
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
Toronto, Ontario--(Newsfile Corp. - August 11, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a life sciences company focused on personalized medicines, today announced the establishment of PERSONALIZ3D™, an integrated ecosystem that will combine telehealth, pharmaceutical 3D printing, and pharmacy fulfillment to support the delivery of personalized medicines. PERSONALIZ3D™ expands PharmaTher's previously announced Personaliz3D P
Biotechnology, Pharmaceuticals
2026-08-11 8:00 AM EDT | PharmaTher Holdings Ltd.
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL® gene-silencing technology, today announced the receipt of a U.S. Notice of Allowance for a patent covering PH-894, further strengthening the Company's intellectual property portfolio. The patent allowance represents a critical milestone in protecting Phio's stra
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-11 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update
British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) -
Biotechnology, Pharmaceuticals, Health
2026-08-11 6:30 AM EDT | BioHarvest Sciences Inc.
Restart Life Sciences Announces Production Launch of New Holy Crap Protein Line
Vancouver, British Columbia--(Newsfile Corp. - August 11, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"), has officially commenced commercial production of its highly anticipated new protein-focused product line. This marks a significant milestone in the Company's product development roadmap and underscores its core focus on revenue gener
Technology, Biotechnology, Health
2026-08-11 6:00 AM EDT | Restart Life Sciences Corp.
BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance
British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences I
Biotechnology, Pharmaceuticals, Health
2026-08-11 6:00 AM EDT | BioHarvest Sciences Inc.
Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date
Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investments Commercial traction observed to date reinforces Medexus confidence in the growth trajectory of GRAFAPEX Management to host conference call at 8:00 AM Eastern time on Tuesday, August 11, 2026
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-10 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Theralase(R) Announces $5 Million Brokered LIFE Offering
Toronto, Ontario--(Newsfile Corp. - August 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC" or the "Age
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-10 5:15 PM EDT | Theralase Technologies Inc.
Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones
White Bear Lake, Minnesota--(Newsfile Corp. - August 10, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today re
Biotechnology, Healthcare and Hospitals
2026-08-10 8:00 AM EDT | Envoy Medical, Inc.
Theralase(R) Grants Stock Options
Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, announces the grant of stock options. The Company has granted an aggregate of 7,000,000 stock options to eligible par
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-07 5:25 PM EDT | Theralase Technologies Inc.
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Encinitas, Califfornia--(Newsfile Corp. - August 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today reported financial results for the second quarter ended June 30, 2026, and provided an update on its clinical pipeline of small-molecule therapies for retinal diseases and its corporate development activities. Second Quarter 2026 and Recent Highlights Advanced enrollment in the Phase 2 ABACUS-2 clinical trial of KIO-301 into the higher-dose cohort
Biotechnology, Pharmaceuticals
2026-08-07 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - August 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminat
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-06 4:05 PM EDT | Phio Pharmaceuticals Corp.
Noveris Health Sciences Inc. Unaware of Any Material Change
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2026) - At the request of CIRO, Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. Noveris is a Canadian life sciences company focused on opportunities in mental health and therapeutic innovation. A
2026-08-06 2:05 PM EDT | Noveris Health Sciences Inc.
AquaBounty Technologies Announces Expansion of Strategic Alternatives Review to Include Power Infrastructure Development Opportunities
Harvard, Massachusetts--(Newsfile Corp. - August 6, 2026) - AquaBounty Technologies, Inc. (NASDAQ: AQB) ("AquaBounty," "we," "our" or the "Company") today announced that it is expanding its ongoing strategic review process for its Pioneer, Ohio property to include opportunities related to power infrastructure and energy development. The Company has previously been engaged in efforts to monetize the Pioneer property through discussions with parties in the aquaculture industry. While th
Agriculture, Biotechnology, Food / Beverages
2026-08-06 8:30 AM EDT | AquaBounty Technologies, Inc.
Britannia Announces Normal Course Issuer Bid
Toronto, Ontario--(Newsfile Corp. - August 5, 2026) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") announces that further to its news release dated May 21, 2026, the Company will commence a normal course issuer bid ("NCIB") to purchase for cancelation, from time to time over a 12-month period starting August 10, 2026, common shares ("Common Shares") of the Company in an aggregate amount of up to 8,112,717 Common Shares, representing 5% of Britannia's issued and outs
Biotechnology, Household / Consumer / Cosmetics, Health, Cannabis Ancillary Service Provider
2026-08-05 8:30 AM EDT | Britannia Life Sciences Inc
PreveCeutical Closes Fourth Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated July 27, 2026, June 12, 2026, May 12, 2026 and April 22, 2026 (the "Prior News Releases"), it has closed a fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement (the "Offering"),
Biotechnology, Pharmaceuticals, Health
2026-08-04 5:20 PM EDT | PreveCeutical Medical Inc.
TempraMed Announces Strategic Partnership with Stealth Health, a Leading Telemedicine Platform for Longevity and Wellness
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a strategic partnership with Stealth Health (stealth.health), a leading telemedicine platform for longevity and precision wellness in North America. The agreement integrates TempraMed's VIVI product portfolio into
Technology, Biotechnology, Pharmaceuticals, Health
2026-08-04 7:00 AM EDT | TempraMed Technologies Ltd.
Theralase(R) Engages Global One Media to Expand Global Investor Awareness
Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has engaged Global One Media Group Pte. Ltd. ("Global One Media") to provide digital
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-04 7:00 AM EDT | Theralase Technologies Inc.
Telo Genomics Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces the grant of stock options (the "Options") pursuant to its stock option plan to purchase up to an aggregate of 3,300,000 common shares of the Company, subject to TSX Venture Exchange
2026-08-04 6:30 AM EDT | Telo Genomics Corp.